Enlivex Therapeutics Ltd.

NasdaqCM:ENLV 주식 보고서

시가총액: US$26.9m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Enlivex Therapeutics 관리

관리 기준 확인 1/4

Enlivex Therapeutics' CEO는 Oren Hershkovitz, Nov2019 에 임명되었습니다 의 임기는 4.58 년입니다. 는 $ 33.59K 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 33.59K. 경영진과 이사회의 평균 재임 기간은 각각 4.6 년과 1.6 년입니다.

주요 정보

Oren Hershkovitz

최고 경영자

n/a

총 보상

CEO 급여 비율n/a
CEO 임기4.6yrs
CEO 소유권0.1%
경영진 평균 재임 기간4.6yrs
이사회 평균 재임 기간1.6yrs

최근 관리 업데이트

Recent updates

We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Apr 04
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Dec 13
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Jul 25
Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation

Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Apr 05
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?

Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Nov 16
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30

Enlivex to gets US patent covering use of cell therapy Allocetra

Sep 06

Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells

Aug 29

Envilex Therapeutics reports Q2 results

Aug 22

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Jul 08
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment

Jul 06

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Mar 23
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Nov 25
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Aug 12
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth

Enlivex issued European patent covering therapeutic compositions of Allocetra immunotherapy

Jun 15

Enlivex issued new Canadian patent for Allocetra immunotherapy

Jun 01

We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Apr 29
We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn

Enlivex shares rise 20% on positive Allocetra data in COVID-19

Feb 03

Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Jan 11
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth

Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

Nov 19
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?

CEO 보상 분석

Oren Hershkovitz 의 보수는 Enlivex Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$26m

Dec 31 2023n/an/a

-US$29m

Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022n/an/a

-US$31m

Sep 30 2022n/an/a

-US$29m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021n/an/a

-US$14m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020n/an/a

-US$12m

Sep 30 2020n/an/a

-US$9m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$8m

Dec 31 2019US$296kUS$38k

-US$10m

보상 대 시장: US 시장에서 비슷한 규모의 회사에 비해 Oren 의 총 보상이 합리적인지 여부를 입증하기에는 데이터가 부족합니다.

보상과 수익: Oren 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Oren Hershkovitz (47 yo)

4.6yrs

테뉴어

US$295,600

보상

Dr. Oren Hershkovitz, Ph.D. serves as Chief Executive Officer at Enlivex Therapeutics Ltd. since November 16, 2019. Dr. Hershkovitz served for nearly a decade in managerial and executive roles at PROLOR Bi...

리더십 팀

이름위치테뉴어보상소유권
Shai Novik
Executive Chairman10.4yrsUS$536.00k3.79%
$ 1.0m
Oren Hershkovitz
Chief Executive Officer4.6yrsUS$295.60k0.12%
$ 33.6k
Shachar Shlosberger
Chief Financial Officer8.4yrsUS$132.00k0.0092%
$ 2.5k
Veronique Amor-Baroukh
Senior Director of Operations2.4yrs데이터 없음데이터 없음
Sigal Arad
Director of HR2.4yrs데이터 없음데이터 없음

4.6yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: ENLV 의 관리팀은 경험 ( 4.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Shai Novik
Executive Chairman10.4yrsUS$536.00k3.79%
$ 1.0m
Andrew Singer
Independent Director1.2yrs데이터 없음데이터 없음
Abraham Havron
Independent Director10.4yrs데이터 없음0.88%
$ 236.6k
Mitchell Levy
Clinical Advisorno data데이터 없음데이터 없음
Roger Pomerantz
Independent Vice Chairman of the Board2.1yrs데이터 없음0%
$ 0
Brian Schwartz
Director3.6yrs데이터 없음0.0089%
$ 2.4k
Clifford Deutschman
Clinical Advisorno data데이터 없음데이터 없음
David Hunter
Clinical Advisorless than a year데이터 없음데이터 없음
Bruno Francois
Clinical Advisorless than a year데이터 없음데이터 없음
Gili Hart
Independent Director10.4yrs데이터 없음0.017%
$ 4.4k
Ali Mobasheri
Clinical Advisorless than a year데이터 없음데이터 없음
Tobias Winkler
Clinical Advisorless than a year데이터 없음데이터 없음

1.6yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ENLV 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.